BIA 28-6156 60 mg clinical trials

Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD

This study looks into a new drug, BIA 28-6156, for people with Parkinson's disease linked to a specific gene change (GBA1). It aims to see if the drug can slow down the worsening of movement problems over 78 weeks, compared to a dummy drug.